If you have looked at ingredient lists of hair serums marketed for growth, you may have seen two copper peptide names: GHK-Cu and AHK-Cu. They are related but distinct compounds with different research records. Here is what each one is and what the evidence shows for hair specifically.
How AHK-Cu Differs From GHK-Cu
GHK-Cu (copper tripeptide-1, glycine-histidine-lysine) is the better-known and more broadly studied compound, with a wide-ranging biological literature covering wound healing, anti-aging signaling, and dermal remodeling. AHK-Cu (copper tripeptide-3, alanine-histidine-lysine) is structurally related and also binds copper, but has a slightly different tripeptide sequence that gives it distinct receptor interactions.
The key distinction in the hair science literature is that AHK-Cu has the most direct published evidence for hair follicle effects specifically, while GHK-Cu has the broader regenerative biology and is more commonly cited in dermatology reviews. In practice, most high-quality hair serums combine both.
The Pyo 2007 Study: What It Actually Showed
The key AHK-Cu study is Pyo HK et al., published in Archives of Pharmaceutical Research in 2007. Using ex vivo human hair follicle organ culture, the researchers found:
- AHK-Cu elongated human hair follicles in culture, consistent with extending the anagen phase of active hair growth
- Increased dermal papilla cell proliferation at picomolar to nanomolar concentrations. Dermal papilla cells are the signaling cells that drive follicle cycling and hair shaft production
- Raised VEGF expression, supporting improved blood supply to the follicle
- Reduced dermal papilla cell apoptosis, supporting follicle cell survival and extending active follicle function
These are meaningful mechanistic findings. Ex vivo organ culture is a robust model that uses actual human follicles rather than cell lines, and the concentrations at which effects were observed are physiologically plausible for a well-formulated topical.
Why This Is Lab Evidence, Not a Clinical Regrowth Claim
The Pyo study is ex vivo, meaning follicles were cultured outside the body in controlled laboratory conditions. Demonstrating that AHK-Cu extends follicle culture growth and stimulates dermal papilla cells in a lab setting is not the same as demonstrating that a serum containing AHK-Cu increases hair density in a clinical population. The gap between ex vivo findings and clinical outcomes is real and common in hair science.
Present AHK-Cu as a well-mechanistically-supported ingredient with the best available preclinical hair evidence, not as a clinically proven regrowth treatment.
How AHK-Cu and GHK-Cu Work Together
Many hair serums combine AHK-Cu and GHK-Cu because their mechanisms complement each other. GHK-Cu contributes the broader anti-inflammatory signaling, dermal remodeling, and VEGF effects documented in the Pickart and Margolina 2018 review. AHK-Cu contributes the more follicle-specific dermal papilla proliferation and direct follicle elongation effects from the Pyo 2007 study. The combination addresses multiple aspects of the follicle environment simultaneously.
Delivery, Clean Scalp Prep, and Routine Sequencing
For either copper peptide to reach the follicle effectively, the scalp needs to be free of product buildup and excess sebum. The Detox Scalp Massager supports clean scalp prep before serum application. The Derma Roller enhances penetration depth for the copper peptide actives in Scalp Serum, providing the delivery mechanism the clinical evidence depends on.
Delivery sequence: Detox Scalp Massager first to clear the surface, then Derma Roller to create micro-channels, then Scalp Serum while channels are open. Allow adequate absorption time before applying other products. Three sessions per week, assessed at six months minimum.
For the full copper peptide context, see the GHK-Cu anchor post.
